Considering DM status and complications, SGLT2i users exhibited a higher percentage of insulin use (33.56% vs. 21.05%, SMD = 0.2838), metformin use (95.53% vs. 72.56%, SMD = 0.6606), SU use (46.97% vs. 24.80%, SMD = 0.4749), and DPP-4 inhibitors use (35.96% vs. 20.24%, SMD = 0.3551). This evidence concerns the gene INS and diabetes mellitus.